Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study.

ABSTRACT:

Objective

Rheumatic disease patients on certain immunomodulators are at increased risk of impaired humoral response to SARS-CoV-2 vaccines. We aimed to identify factors associated with breakthrough infection among patients with rheumatic diseases.

Methods

We identified patients with rheumatic diseases being treated with immunomodulators in a large healthcare system who received at least two doses of either the mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) vaccines or one dose of the Johnson & Johnson-Janssen (J&J) vaccine. We followed patients until SARS-CoV-2 infection, death, or December 15, 2021, when the Omicron variant became dominant in our region. We estimated the association of baseline characteristics with the risk of breakthrough infection using multivariable C

SUBMITTER: Patel NJ 

PROVIDER: S-EPMC9605731 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature